Vistagen Therapeutics, Inc. (VTGN) shareholders
Close on Nov 16, 2026Market cap $8.18MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Michael Kramarz Joint filing with Commodore Capital LP (9.90%), Commodore Capital Master LP (9.90%) and 1 more | 4,383,508 | 9.90% | 13G (passive) amendment | Dec 31, 2025 |
| Commodore Capital LP Joint filing with Commodore Capital Master LP (9.90%), Robert Egen Atkinson (9.90%) and 1 more | 4,244,590 | 9.90% | 13G (passive) amendment | Jun 30, 2026 |
| Bvf Partners L P/Il Joint filing with Bvf Inc/Il (9.97%), Lampert Mark N (9.97%) and 3 more | 3,084,324 | 9.97% | 13G (passive) amendment | Dec 31, 2024 |
| Chen Yu Joint filing with TCG Crossover GP II, LLC (5.10%), TCG Crossover Fund II, L.P. (5.10%) | 2,960,404 | 6.70% | 13G (passive) amendment | Jun 30, 2026 |
| Great Point Partners, LLC Joint filing with Dr. Jeffrey R. Jay, M.D. (6.59%), Ms. Lillian Nordahl (6.59%) | 2,055,834 | 6.59% | 13G (passive) amendment | Jun 30, 2025 |
| Ms. Lillian Nordahl Joint filing with Great Point Partners, LLC (6.28%), Dr. Jeffrey R. Jay, M.D. (6.28%) | 2,055,834 | 6.28% | 13G (passive) amendment | Sep 30, 2025 |
| Stempoint Capital LP Joint filing with Stempoint Capital Management Gp LLC (6.50%), Michelle Ross (6.50%) | 1,790,182 | 6.50% | 13G (passive) | Dec 31, 2023 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of VTGN | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Commodore Capital LP | 2,788,620 | 6.28% | $630.23K | New | 0.04% |
| Vanguard Capital Management LLC | 1,574,200 | 3.55% | $355.77K | – | 0.00% |
| Two Sigma Investments, LP | 847,992 | 1.91% | $191.65K | +378,373 | 0.00% |
| Acadian Asset Management LLC | 794,579 | 1.79% | $178.00K | +204,916 | 0.00% |
| Renaissance Technologies LLC | 730,500 | 1.65% | $165.09K | +439,200 | 0.00% |
| Stempoint Capital LP | 616,749 | 1.39% | $17.28K | −616,749 | 0.00% |
| Ikarian Capital, LLC | 519,077 | 1.17% | $117.31K | – | 0.01% |
| AdvisorShares Investments LLC | 438,643 | 0.99% | $99.13K | +161,533 | 0.01% |
| Luminus Management LLC | 403,115 | 0.91% | $91.10K | +7,062 | 0.06% |
| Geode Capital Management, LLC | 365,002 | 0.82% | $82.51K | −88,389 | 0.00% |
| ADAR1 Capital Management, LLC | 351,141 | 0.79% | $79.36K | −400,000 | 0.00% |
| BlackRock, Inc. | 345,432 | 0.78% | $78.07K | −103,075 | 0.00% |
| Group One Trading, L.P. | 304,385 | 0.69% | $68.79K | +284,510 | 0.00% |
| Verdad Advisers, LP | 293,343 | 0.66% | $66.30K | +108,405 | 0.06% |
| Vanguard Fiduciary Trust Co | 217,700 | 0.49% | $49.20K | – | 0.00% |
| Jane Street Group, LLC | 164,827 | 0.37% | $37.25K | −107,984 | 0.00% |
| Boothbay Fund Management, LLC | 134,571 | 0.30% | $30.41K | – | 0.00% |
| State Street Corp | 121,114 | 0.27% | $27.37K | – | 0.00% |
| XTX Topco Ltd | 118,380 | 0.27% | $26.75K | −34,469 | 0.00% |
| Northern Trust Corp | 80,823 | 0.18% | $18.27K | +8,168 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 49 | 12M | 26.5% | 10 / 15 | 14 / 16 | 5M | 8M |
| Q1 2026 | 56 | 15M | 34.6% | 16 / 15 | 9 / 14 | 5M | 1M |
| Q4 2025 | 55 | 14M | 31.0% | 14 / 18 | 15 / 16 | 3M | 13M |
| Q3 2025 | 58 | 24M | 53.9% | 14 / 19 | 10 / 7 | 10M | 1M |
| Q2 2025 | 51 | 15M | 34.9% | 6 / 17 | 12 / 3 | 0M | 1M |
| Q1 2025 | 48 | 16M | 35.9% | 3 / 12 | 20 / 9 | 1M | 1M |
| Q4 2024 | 54 | 16M | 35.0% | 15 / 19 | 10 / 8 | 4M | 3M |
| Q3 2024 | 47 | 15M | 34.4% | 9 / 9 | 14 / 3 | 4M | 3M |
| Q2 2024 | 42 | 15M | 34.2% | 7 / 8 | 14 / 6 | 2M | 1M |
| Q1 2024 | 41 | 15M | 33.0% | 7 / 12 | 10 / 11 | 1M | 3M |
| Q4 2023 | 45 | 17M | 37.7% | 23 / 16 | 2 / 12 | 14M | 1M |
| Q3 2023 | 34 | 3M | 6.8% | 13 / 11 | 7 / 11 | 2M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
18 funds held VTGN in Q1 2026, 80% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of VTGN | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,160,455 | 2.61% | $262.26K | 0.00% | Jun 30, 2026 |
| AdvisorShares Psychedelics ETF | 438,643 | 0.99% | $99.13K | 0.22% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 413,745 | 0.93% | $93.51K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 266,141 | 0.60% | $167.67K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 48,903 | 0.11% | $30.81K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 46,961 | 0.11% | $29.59K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 12,189 | 0.03% | $7.68K | 0.00% | May 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | 4,947 | 0.01% | $1.12K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Shawn Singh | President and CEO, Director | 75,721 | 0.17% | Jul 2, 2026 |
| Nick B. Tressler | Chief Financial Officer | 11,712 | 0.03% | Jul 2, 2026 |
| Reid G. Adler | Chief Legal Officer | 60,868 | 0.14% | Jul 2, 2026 |
| Angel S. Angelov | Chief Medical Officer | – | – | May 19, 2026 |
| Joshua S. Prince | Chief Operating Officer | 15,249 | 0.03% | Apr 9, 2026 |
| Elissa S. Cote | Chief Corp Development Officer | – | – | Apr 9, 2026 |
| Cynthia Lynn Anderson | CHIEF FINANCIAL OFFICER | 12,801 | 0.03% | Jul 1, 2025 |
| Douglas J. Williamson | Director | – | – | Jul 31, 2026 |
| Paul R. Edick | Director | – | – | Nov 4, 2025 |
| Joanne Curley | Director | – | – | Sep 11, 2025 |
| Mary L. Rotunno | Director | – | – | Sep 11, 2025 |
| Ann Michelle Cunningham | Director | – | – | Sep 11, 2025 |
| Jon S. Saxe | Director | 55,751 | 0.13% | Sep 11, 2025 |
| Margaret M. FitzPatrick | Director | – | – | Sep 11, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Reid G. Adler Chief Legal Officer | Jun 30, 2026 | Award | +36,818 | $0.19 | $7.00K | 60,868 |
| Nick B. Tressler Chief Financial Officer | Jun 30, 2026 | Award | +11,712 | $0.19 | $2.23K | 11,712 |
| Shawn Singh President and CEO, Director | Jun 30, 2026 | Award | +36,818 | $0.19 | $7.00K | 54,846 |
| Joshua S. Prince Chief Operating Officer | Dec 31, 2025 | Award | +4,386 | $0.56 | $2.46K | 15,249 |
| Shawn Singh President and CEO, Director | Jun 30, 2025 | Award | +7,541 | $1.70 | $12.82K | 18,028 |
| Reid G. Adler Chief Legal Officer | Jun 30, 2025 | Award | +7,541 | $1.70 | $12.82K | 24,050 |
| Joshua S. Prince Chief Operating Officer | Jun 30, 2025 | Award | +4,882 | $1.70 | $8.30K | 10,863 |
| Cynthia Lynn Anderson CHIEF FINANCIAL OFFICER | Jun 30, 2025 | Award | +6,617 | $1.70 | $11.25K | 12,801 |
| Cynthia Lynn Anderson CHIEF FINANCIAL OFFICER | Dec 31, 2024 | Award | +2,592 | $2.51 | $6.51K | 6,184 |
| Joshua S. Prince Chief Operating Officer | Dec 31, 2024 | Award | +3,310 | $2.51 | $8.31K | 5,981 |
| Reid G. Adler CHF CORP DEVEL OFF, GEN COUNS | Jun 28, 2024 | Award | +4,854 | $2.96 | $14.37K | 16,509 |
| Joshua S. Prince Chief Operating Officer | Jun 28, 2024 | Award | +2,671 | $2.96 | $7.91K | 2,671 |
| Shawn Singh CHIEF EXECUTIVE OFFICER, Director | Jun 28, 2024 | Award | +4,854 | $2.96 | $14.37K | 10,487 |
| Cynthia Lynn Anderson CHIEF FINANCIAL OFFICER | Jun 28, 2024 | Award | +3,592 | $2.96 | $10.63K | 3,592 |
| Shawn Singh CHIEF EXECUTIVE OFFICER, Director | Dec 29, 2023 | Award | +167 | $1.72 | $287 | 5,633 |
| Reid G. Adler CHF CORP DEVEL OFF, GEN COUNS | Dec 29, 2023 | Award | +167 | $1.72 | $287 | 11,655 |
| Capital Lp Commodore 10% owner | Aug 7, 2023 | Buy | +775,756 | $23.15 | $17.96M | 1,575,000 |
| Jerrold Duane Dotson VP, CFO | Jun 30, 2023 | Award | +167 | $1.59 | $266 | 3,671 |
| Shawn Singh CHIEF EXECUTIVE OFFICER, Director | Jun 30, 2023 | Award | +167 | $1.59 | $266 | 5,466 |
| Reid G. Adler CHIEF LEGAL OFFICER | Jun 30, 2023 | Award | +167 | $1.59 | $266 | 11,488 |
| Jerrold Duane Dotson VP, CFO AND SECRETARY | Dec 30, 2022 | Award | +5,000 | $0.09 | $450 | 105,111 |
| Shawn Singh CHIEF EXECUTIVE OFFICER, Director | Dec 30, 2022 | Award | +5,000 | $0.09 | $450 | 158,998 |
| Jerry B. Gin Director | Aug 18, 2022 | Buy | +100,000 | $0.18 | $18.00K | 100,000 |
| Jerry B. Gin Director | Aug 18, 2022 | Buy | +100,000 | $0.18 | $18.00K | 100,000 |
| Reid G. Adler CHIEF LEGAL OFFICER | Aug 17, 2022 | Buy | +300,000 | $0.17 | $51.00K | 334,629 |
| Shawn Singh CHIEF EXECUTIVE OFFICER, Director | Aug 17, 2022 | Buy | +600,000 | $0.17 | $102.00K | 626,234 |
| Jerrold Duane Dotson VP, CFO AND SECRETARY | Jul 30, 2022 | Award | +5,000 | $0.75 | $3.75K | 100,111 |
| VHCP Management II, LLC 10% owner | Jul 12, 2022 | Sale | −60,000 | $0.89 | $53.40K | 20,637,286 |
| Shawn Singh CHIEF EXECUTIVE OFFICER, Director | Jun 30, 2022 | Award | +5,000 | $0.75 | $3.75K | 153,998 |
| Mark Alan Smith CHIEF MEDICAL OFFICER | Jun 30, 2022 | Award | +5,000 | $0.75 | $3.75K | 19,915 |
| Shawn Singh CHIEF EXECUTIVE OFFICER, Director | May 12, 2022 | Option exercise | +100,000 | $1.00 | $100.00K | 148,998 |
| Jerrold Duane Dotson VP, CFO AND SECRETARY | Jan 11, 2022 | Option exercise | +18,750 | $1.00 | $18.75K | 94,571 |
| Shawn Singh CHIEF EXECUTIVE OFFICER, Director | Dec 31, 2021 | Award | +3,623 | $1.66 | $6.01K | 48,998 |
| Mark Alan Smith CHIEF MEDICAL OFFICER | Dec 31, 2021 | Award | +2,655 | $1.66 | $4.41K | 14,915 |
| 1415876 PRES./CHIEF SCIENTIFIC OFFICER | Dec 31, 2021 | Award | +3,623 | $1.66 | $6.01K | 64,958 |
| Jerrold Duane Dotson VP, CFO AND SECRETARY | Dec 31, 2021 | Award | +3,575 | $1.66 | $5.93K | 75,821 |
| Jerrold Duane Dotson VP, CFO AND SECRETARY | Sep 7, 2021 | Sale | −30,000 | $3.13 | $93.90K | 72,786 |
| 1415876 PRES./CHIEF SCIENTIFIC OFFICER | Sep 2, 2021 | Gift | +1,111 | – | – | 61,335 |
| 1415876 PRES./CHIEF SCIENTIFIC OFFICER | Aug 23, 2021 | Gift | −740 | – | – | 33,901 |
| 1415876 PRES./CHIEF SCIENTIFIC OFFICER | Aug 17, 2021 | Buy | +3,750 | $2.73 | $10.24K | 34,641 |
| Mark Alan Smith CHIEF MEDICAL OFFICER | Jun 30, 2021 | Award | +2,260 | $1.95 | $4.41K | 12,260 |
| Jerrold Duane Dotson VP, CFO AND SECRETARY | Jun 30, 2021 | Award | +3,044 | $1.95 | $5.94K | 13,044 |
| Jerrold Duane Dotson VP, CFO AND SECRETARY | Jun 30, 2021 | Option exercise | +1,000 | $1.50 | $1.50K | 14,044 |
| Jerrold Duane Dotson VP, CFO AND SECRETARY | Jun 30, 2021 | Option exercise | +78,918 | $1.00 | $78.92K | 92,962 |
| Jerrold Duane Dotson VP, CFO AND SECRETARY | Jun 30, 2021 | Option exercise | +9,824 | $0.40 | $3.93K | 102,786 |
| Shawn Singh CHIEF EXECUTIVE OFFICER, Director | Jun 30, 2021 | Award | +5,000 | $1.95 | $9.75K | 45,375 |
| 1415876 PRES./CHIEF SCIENTIFIC OFFICER | Jun 30, 2021 | Award | +3,391 | $1.95 | $6.61K | 91,115 |
| Shawn Singh CHIEF EXECUTIVE OFFICER, Director | Apr 23, 2021 | Option exercise | +5,000 | $1.50 | $7.50K | 40,375 |
| Jon S. Saxe Director | Mar 19, 2021 | Option exercise | +2,500 | $1.50 | $3.75K | 5,751 |
| Brian J. Underdown Director | Mar 19, 2021 | Option exercise | +2,500 | $1.50 | $3.75K | 2,500 |
| Shawn Singh CHIEF EXECUTIVE OFFICER, Director | Dec 31, 2020 | Award | +5,000 | $0.45 | $2.25K | 35,375 |
| Jerrold Duane Dotson VP, CFO AND SECRETARY | Dec 31, 2020 | Award | +5,000 | $0.45 | $2.25K | 10,000 |
| 1415876 PRES./CHIEF SCIENTIFIC OFFICER, Director | Dec 31, 2020 | Award | +5,000 | $0.45 | $2.25K | 87,724 |
| Mark Alan Smith CHIEF MEDICAL OFFICER | Dec 31, 2020 | Award | +5,000 | $0.45 | $2.25K | 10,000 |
| Jon S. Saxe Director | Aug 21, 2020 | Buy | +30,000 | $0.69 | $20.70K | 50,000 |
| 1415876 PRES./CHIEF SCIENTIFIC OFFICER, Director | Jun 30, 2020 | Award | +5,000 | $0.45 | $2.25K | 67,724 |
| Shawn Singh CHIEF EXECUTIVE OFFICER, Director | Jun 30, 2020 | Award | +5,000 | $0.45 | $2.25K | 30,375 |
| Mark Alan Smith CHIEF MEDICAL OFFICER | Jun 30, 2020 | Award | +5,000 | $0.45 | $2.25K | 5,000 |
| Jerrold Duane Dotson VP, CFO AND SECRETARY | Jun 30, 2020 | Award | +5,000 | $0.45 | $2.25K | 5,000 |
| 1415876 PRES./CHIEF SCIENTIFIC OFFICER, Director | Nov 20, 2019 | Buy | +15,000 | $0.34 | $5.10K | 15,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Vistagen Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 2,641,884 shares on Sep 24, 2026 over the last 90 days.
See a number that looks wrong?